Changchun High-Tech: Clinical trial application for subsidiary's GenSci161 injection accepted

Changchun High-Tech announced on October 13 that its controlling subsidiary, Changchun GeneScience Pharmaceutical Co., Ltd., received a Notice of Acceptance issued upon approval by the National Medical Products Administration, and the domestic production drug registration clinical trial application for GenSci161 Injection has been accepted. GenSci161 Injection is a Class 1 therapeutic biologic independently developed by GeneScience Pharmaceutical. It is a novel fully human monoclonal IgG1 bispecific antibody and is intended for the treatment of recurrent pericarditis.